Your browser is no longer supported. Please, upgrade your browser.
Settings
CAPR [NASD]
Capricor Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.94 Insider Own2.27% Shs Outstand20.41M Perf Week-8.66%
Market Cap92.07M Forward P/E- EPS next Y-1.06 Insider Trans0.00% Shs Float19.93M Perf Month-24.20%
Income-13.70M PEG- EPS next Q- Inst Own6.50% Short Float2.17% Perf Quarter-17.15%
Sales0.30M P/S306.90 EPS this Y57.40% Inst Trans19.74% Short Ratio0.63 Perf Half Y-17.32%
Book/sh1.38 P/B2.91 EPS next Y-6.00% ROA-44.70% Target Price- Perf Year172.79%
Cash/sh1.42 P/C2.82 EPS next 5Y- ROE-54.70% 52W Range1.40 - 12.32 Perf YTD16.91%
Dividend- P/FCF- EPS past 5Y35.90% ROI-43.10% 52W High-67.45% Beta6.52
Dividend %- Quick Ratio11.30 Sales past 5Y-43.80% Gross Margin- 52W Low186.43% ATR0.30
Employees26 Current Ratio11.30 Sales Q/Q-50.00% Oper. Margin- RSI (14)29.66 Volatility6.42% 6.38%
OptionableYes Debt/Eq0.13 EPS Q/Q39.50% Profit Margin- Rel Volume0.46 Prev Close4.02
ShortableYes LT Debt/Eq0.12 EarningsMar 11 AMC Payout- Avg Volume682.77K Price4.01
Recom2.00 SMA20-14.39% SMA50-29.44% SMA200-23.62% Volume317,136 Change-0.25%
Dec-26-18Downgrade Maxim Group Buy → Hold
Jan-26-18Reiterated H.C. Wainwright Buy $6.50 → $8.60
Sep-15-17Reiterated H.C. Wainwright Buy $2.15 → $6.50
Feb-13-17Resumed Rodman & Renshaw Buy $14
Jul-06-16Resumed H.C. Wainwright Buy $13
Jun-15-16Initiated ROTH Capital Buy
Mar-13-21 01:28AM  
Mar-11-21 04:01PM  
02:30PM  
Mar-09-21 09:15AM  
Mar-04-21 09:00AM  
Feb-01-21 09:15AM  
Jan-19-21 09:15AM  
Jan-12-21 09:05AM  
Dec-29-20 09:15AM  
Nov-24-20 07:30AM  
Nov-12-20 04:01PM  
02:30PM  
Nov-09-20 09:15AM  
Nov-05-20 09:00AM  
Sep-23-20 09:25AM  
Sep-10-20 09:15AM  
Sep-01-20 04:34PM  
Aug-31-20 09:00AM  
Aug-25-20 11:34AM  
09:15AM  
Aug-06-20 04:01PM  
Jul-30-20 09:15AM  
Jul-28-20 12:33PM  
Jul-23-20 07:28AM  
Jun-04-20 09:15AM  
May-29-20 01:08PM  
May-26-20 09:25AM  
May-14-20 05:35PM  
04:01PM  
May-13-20 04:30PM  
07:00AM  
May-06-20 06:44PM  
Apr-30-20 12:23AM  
Apr-29-20 09:15AM  
Apr-24-20 07:31AM  
Apr-13-20 09:00AM  
Apr-06-20 04:02PM  
Apr-03-20 08:00AM  
Mar-24-20 08:00AM  
Mar-19-20 08:30AM  
Mar-18-20 04:01PM  
02:30PM  
Mar-17-20 08:00AM  
Mar-11-20 04:30PM  
Mar-10-20 07:01AM  
Feb-13-20 11:30AM  
Feb-07-20 04:12PM  
Feb-03-20 07:39AM  
Jan-28-20 07:01AM  
Dec-19-19 01:14PM  
Dec-17-19 01:52PM  
Dec-11-19 05:29AM  
Nov-07-19 05:15PM  
04:00PM  
Nov-01-19 09:00AM  
Oct-27-19 09:16AM  
Oct-21-19 09:25AM  
Oct-14-19 09:35AM  
Oct-07-19 12:27PM  
06:30AM  
Oct-04-19 10:09AM  
Oct-02-19 09:15AM  
Oct-01-19 09:14AM  
Sep-26-19 11:24AM  
09:47AM  
Sep-25-19 08:44AM  
Sep-24-19 11:25AM  
09:20AM  
07:42AM  
07:30AM  
Sep-23-19 09:44AM  
Sep-21-19 08:20AM  
Sep-20-19 09:12AM  
Sep-19-19 08:41AM  
Sep-17-19 12:29PM  
08:38AM  
07:00AM  
Sep-11-19 09:04AM  
Sep-06-19 07:30AM  
Aug-23-19 08:37AM  
Aug-22-19 07:31AM  
Aug-20-19 09:03AM  
Aug-16-19 10:24AM  
Aug-06-19 06:05PM  
04:00PM  
Aug-01-19 10:32AM  
Jul-30-19 08:00AM  
Jul-25-19 07:00AM  
Jul-17-19 07:00AM  
Jul-16-19 12:44PM  
Jul-15-19 02:59PM  
08:45AM  
06:00AM  
Jul-02-19 02:23PM  
May-13-19 05:15PM  
04:06PM  
04:00PM  
02:30PM  
May-06-19 04:00PM  
Apr-05-19 10:52AM  
Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment of cardiac conditions, including heart failure and post myocardial infarction with cardiac dysfunction. It is also developing CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in preclinical stage for the potential prevention of COVID-19. Capricor collaborates with Lonza Houston, Inc. for the development of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in Beverly Hills, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Manzo LouisDirectorSep 24Option Exercise3.708,29930,70644,603Sep 28 08:30 AM
Marban LindaCHIEF EXECUTIVE OFFICERJul 27Option Exercise3.7041,497153,53962,367Jul 29 06:39 PM